Delving into the Latest Updates on Recepta Biopharma SA with Synapse

Overview

Tags

Neoplasms

Urogenital Diseases

Endocrinology and Metabolic Disease

Monoclonal antibody

Radiolabeled antibody

Recombinant polypeptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	11
Endocrinology and Metabolic Disease	6
Hemic and Lymphatic Diseases	2
Immune System Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Monoclonal antibody	7
Radiolabeled antibody	2
Recombinant polypeptide	2
Diagnostic radiopharmaceuticals	1
Therapeutic radiopharmaceuticals	1

Top 5 Target	Count

NaPi-2b(Sodium-dependent phosphate transport protein 2B)	2
Lewis B antigen	2
PD-1(Programmed cell death protein 1)	1
A34(A34 protein)	1
CTLA4(Cytotoxic T-Lymphocyte-Associated Antigen 4)	1

The humanized monoclonal antibody against Lewis Y antigen (Hu3S193) has been demonstrated to be safe in previous studies and has also been indicated as potential intervention in breast cancer. The study of this new agent in advanced breast cancer may contribute to the development of new strategies for patients that progressed after hormonal treatment.

Start Date01 Nov 2013

Sponsor / Collaborator

Instituto do Cancer do Estado de Sao Paulo

[+2]

NCT01137071 / TerminatedPhase 2

A Phase II Trial of Hu3S193 Consolidation Therapy for Patients With Relapsing Platinum-sensitive Ovarian, Primary Peritoneal and Fallopian Tubes Adenocarcinoma, Who Achieved a Second Complete Response

RATIONALE: Monoclonal antibodies, such as Hu3S193, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
PURPOSE: This phase II trial is studying how well Hu3S193 works as a consolidation therapy for women with relapsing platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer.

Start Date01 Apr 2011

Sponsor / Collaborator

Recepta Biopharma SA

100 Clinical Results associated with Recepta Biopharma SA

Login to view more data

0 Patents (Medical) associated with Recepta Biopharma SA

Login to view more data

100 Deals associated with Recepta Biopharma SA

Login to view more data

100 Translational Medicine associated with Recepta Biopharma SA

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

6

Preclinical

Phase 2

2

1

NDA/BLA

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Balstilimab ( PD-1 )	Uterine Cervical Cancer More	NDA/BLA
Zalifrelimab ( CTLA4 )	Non-Small Cell Lung Cancer More	Phase 2
RebmAb400 ( A34 )	Adenocarcinoma More	Preclinical
211At-Rebmab200 ( NaPi-2b )	Ovarian Cancer More	Preclinical
99mTc-Rebmab200 ( NaPi-2b )	Ovarian Cancer More	Preclinical